Skip to content

Analgesic effect of lidocaine/propitocaine eutectic mixture patch

Assessment of efficacy of EMLA (eutectic micture of lidocaine and propitocaine) patch for venipuncture.

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT1041240045
Enrollment
190
Registered
2024-06-13
Start date
2024-06-13
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Not applicable (healthy adult)

Interventions

Trial 1 Group A : Venipuncture using a 24G indwelling needle after 30 minutes of penless tape application. Group B : Venipuncture using a 22G indwelling needle after 30 minutes of penless tape applica

Sponsors

Goto Takashi
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1) Healthy individuals (equivalent to ASA-PS class 1,2) 2) Sex: male 3) Age: between 18 and 45 years old 4) Those who voluntarily provided written informed consent upon receiving sufficient explanation and understanding the content of the study

Exclusion criteria

Exclusion criteria: 1) Persons with a history of drug allergies. 2) Persons with a history of contact dermatitis in response to topical medication. 3) Persons with or a history of severe liver disease, kidney disease, circulatory disease. 4) Persons whose veins are difficult to identify on the dorsum of the hand, forearm, elbow fossa, or upper arm. 5) Subjects with skin abnormalities (eczema, dermatitis, scars, etc.) that may affect observation of the study drug application site. 6) Persons with Methemoglobinemia. 7) Persons with sensory paralysis in the limbs. 8) Persons who plan to use all drugs except the study drug form the day before the test drug is applied until the end of efficacy evalution. 9) Persons who have already participated in a study of the study drug and have been administered this study drug. 10) Persons who have participated in other research and received the study drug within 120 days of application of the study drug. 11) In addition, persons who are judged by the research-responsible doctor to be inappropriate as subjects.

Design outcomes

Primary

MeasureTime frame
1) Pain assessment using a visual analogue scale 2) Pain assessment using a verbal rating score 3) Pain assessment using current perception threshold

Secondary

MeasureTime frame
1) Pulse rate 2) Blood pressure 3) SpO2 4) ECG Waveform 5) Frequency, rate and severity of adverse events

Contacts

Public ContactKako Sugihara

Asahi University School of Dentistry

sugik2@dent.asahi-u.ac.jp+81-58-329-1479

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026